Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;38(1):e14433.
doi: 10.1111/dme.14433. Epub 2020 Nov 16.

Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic

E G Wilmot  1   2 , A Lumb  3   4 , P Hammond  5 , H R Murphy  6   7 , E Scott  8 , F W Gibb  9   10 , J Platts  11 , P Choudhary  12   13
Affiliations
Review

Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic

E G Wilmot et al. Diabet Med. 2021 Jan.

Abstract

The emergence of continuous glucose monitoring has driven improvements in glycaemic control and quality of life for people with diabetes. Recent changes in access to continuous glucose monitoring systems within UK health services have increased the number of people able to benefit from these technologies. The COVID-19 pandemic has created an opportunity for diabetes healthcare professionals to use continuous glucose monitoring technology to remotely deliver diabetes services to support people with diabetes. This opportunity can be maximized with improved application and interpretation of continuous glucose monitoring-generated data. Amongst the diverse measures of glycaemic control, time in range is considered to be of high value in routine clinical care because it is actionable and is visibly responsive to changes in diabetes management. Importantly, it is also been linked to the risk of developing complications associated with diabetes and can be understood by people with diabetes and healthcare professionals alike. The 2019 International Consensus on Time in Range has established a series of target glucose ranges and recommendations for time spent within these ranges that is consistent with optimal glycaemic control. The recommendations cover people with type 1 or type 2 diabetes, with separate targets indicated for elderly people or those at higher risk from hypoglycaemia, as well as for women with type 1 diabetes during pregnancy. The aim of this best practice guide was to clarify the intent and purpose of these international consensus recommendations and to provide practical insights into their implementation in UK diabetes care.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Time in ranges: targets for people with type 1 or type 2 diabetes. TAR, time above range; TIR, time in range
FIGURE 2
FIGURE 2
Association of time in range with microvascular complications
FIGURE 3
FIGURE 3
Time in ranges: targets for older people with type 1 or type 2 diabetes and those at high risk from hypoglycaemia. TBR, time below range
FIGURE 4
FIGURE 4
Time in ranges: targets for women with type 1 diabetes who are pregnant or planning pregnancy. TAR, time above range; TBR, time below range; TIR, time in range
See this image and copyright information in PMC

References

    1. Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017;317:379‐387. - PubMed
    1. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE‐BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well‐Controlled Type 1 Diabetes. Diabetes Care. 2017;40:538‐545. - PMC - PubMed
    1. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317:371‐378. - PubMed
    1. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. Ann Intern Med. 2017;167:365. - PubMed
    1. Bolinder J, Antuna R, Geelhoed‐Duijvestijn P, Kröger J, Weitgasser R. Novel glucose‐sensing technology and hypoglycaemia in type 1 diabetes: A multicentre, non‐masked, randomised controlled trial. Lancet. 2016;388:2254‐2263. - PubMed

Publication types

MeSH terms

Substances